Payment overview · 2025
General Payments
$1,234.72
67 reported records · 16 companies
Healthcare provider profile · identity verified
Andrew Poe
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SPRINGVILLE, AL · NPI 1811412083
Verified facts
What the public records show
CMS Open Payments records show Andrew Poe received $1,234.72 in general payments during 2025 across 67 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $213.42 | 17.3% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $200.60 | 16.2% | 11 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $193.61 | 15.7% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.85 | 11.7% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.17 | 7.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.72 | 6.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.15 | 5.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.65 | 3.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.16 | 3.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.69 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.61 | 2.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.32 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.39 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.26 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,234.72 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $257.07 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $200.60 | 11 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $193.61 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.72 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.18 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.15 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.76 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.16 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $43.55 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.32 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 259 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 88 |
| Lisinopril | Lisinopril | 189 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 58 |
| Omeprazole | Omeprazole | 121 | 41 |
| Meloxicam | Meloxicam | 95 | 34 |
| Losartan Potassium | Losartan Potassium | 91 | 34 |
| Jardiance | Empagliflozin | 85 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 26 |
| Metformin Hcl Er | Metformin Hcl | 76 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Alendronate Sodium | Alendronate Sodium | 72 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 19 |
| Cefdinir | Cefdinir | 67 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 15 |
| Carvedilol | Carvedilol | 57 | 28 |
| Metformin Hcl | Metformin Hcl | 56 | 22 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 55 | 13 |
| Mounjaro | Tirzepatide | 55 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 35 |
| Eliquis | Apixaban | 53 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 21 |
| Azithromycin | Azithromycin | 52 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 18 |
| Methocarbamol | Methocarbamol | 52 | 29 |
| Trazodone Hcl | Trazodone Hcl | 52 | 22 |
| Benazepril Hcl | Benazepril Hcl | 50 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 39 |
| Simvastatin | Simvastatin | 50 | 18 |
| Furosemide | Furosemide | 49 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 44 |
| Methylprednisolone | Methylprednisolone | 47 | 35 |
| Celecoxib | Celecoxib | 46 | 17 |
| Montelukast Sodium | Montelukast Sodium | 46 | 19 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 15 |
| Famotidine | Famotidine | 40 | 18 |
| Allopurinol | Allopurinol | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 15 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Atenolol | Atenolol | 32 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 14 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 18 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ozempic | Semaglutide | 26 | 12 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Prednisone | Prednisone | 22 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Gabapentin | Gabapentin | 17 | 14 |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Finasteride | Finasteride | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,234.72 · 67 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XHANCE, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error